Skip to content
6-K

Foreign Interim / Material

ProQR Therapeutics N.V. PRQR

0001558370-25-006849

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2025 · Mar 31, 2025 105.3M sh
Shares Diluted Q1 2025 · Mar 31, 2024 81.57M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −€15.8M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −€15.13M
Cash And Equivalents Q1 2025 · Mar 31, 2025 €132.41M
Cash And Equivalents Q1 2025 · Dec 31, 2024 €149.41M
Cash And Equivalents Q1 2025 · Mar 31, 2024 €85.71M
Cash And Equivalents Q1 2025 · Dec 31, 2023 €118.93M
Stockholders Equity Q1 2025 · Mar 31, 2025 €78.94M
Stockholders Equity Q1 2025 · Dec 31, 2024 €88.56M
Stockholders Equity Q1 2025 · Mar 31, 2024 €34.82M
Stockholders Equity Q1 2025 · Dec 31, 2023 €41.39M
Current Liabilities Q1 2025 · Mar 31, 2025 €33.72M
Current Liabilities Q1 2025 · Dec 31, 2024 €38.9M
Total Liabilities Q1 2025 · Mar 31, 2025 €72.75M
Total Liabilities Q1 2025 · Dec 31, 2024 €79.4M
Current Assets Q1 2025 · Mar 31, 2025 €138.08M
Current Assets Q1 2025 · Dec 31, 2024 €153.85M
Total Assets Q1 2025 · Mar 31, 2025 €151.69M
Total Assets Q1 2025 · Dec 31, 2024 €167.96M
Eps Diluted Q1 2025 · Mar 31, 2025 −€0.10
Eps Diluted Q1 2025 · Mar 31, 2024 −€0.09
Eps Basic Q1 2025 · Mar 31, 2025 −€0.10
Eps Basic Q1 2025 · Mar 31, 2024 −€0.09
Rd Expense Q1 2025 · Mar 31, 2025 €12.32M
Rd Expense Q1 2025 · Mar 31, 2024 €9.28M
Net Income Q1 2025 · Mar 31, 2025 −€10.08M
Net Income Q1 2025 · Mar 31, 2024 −€7.66M
Operating Income Q1 2025 · Mar 31, 2025 −€10.82M
Operating Income Q1 2025 · Mar 31, 2024 −€8.08M